FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Clin Case Rep / Cauda equina syndrome in an ovarian malignant-mixed mül...
Clinical case reports2019; 7(12); 2341-2345; doi: 10.1002/ccr3.2472

Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread.

Abstract: Leptomeningeal metastasis is extremely rare in patients with ovarian cancer, but should be considered in patients presenting with neurologic deficits such as cauda equine syndrome. Given its poor prognosis and lack of data currently on management, additional studies are needed to optimize treatment regimens and improve outcomes.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2019-10-22 PubMed ID: 31893054PubMed Central: PMC6935635DOI: 10.1002/ccr3.2472Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Case Reports

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research reveals a highly unusual case where an ovarian cancer spreads to the leptomeninges resulting in cauda equina syndrome. This suggests the need for further studies to optimize treatment due to lack of data and poor prognosis.

Introduction and Background

  • The focus of this paper is on a rare occurrence of leptomeningeal metastasis in a patient with ovarian cancer manifesting as cauda equina syndrome.
  • Leptomeningeal metastasis is a medical condition where cancer cells spread to the membranes (meninges) surrounding the brain and spinal cord.
  • Cauda equina syndrome is a serious neurological condition where something compresses on the spinal nerve roots. In this research, it was caused by ovarian cancer metastasis, an extremely rare scenario.

Findings

  • The study presents this anomaly, as leptomeningeal metastasis represents an infrequent complication in patients suffering from ovarian cancer.
  • It additionally highlights that when patients with ovarian cancer exhibit neurologic deficits like cauda equina syndrome, the possibility of this rare metastasis should be considered.

Implications

  • Due to the rarity of this condition, there is a significant lack of data on managing patients in such situations, leading to a generally poor prognosis.
  • This underscores the urgency for more comprehensive studies to develop improved treatment regimens and outcomes for such patients.

Conclusions

  • The research concludes that although leptomeningeal metastasis in ovarian cancer patients is extremely rare, it should not be overlooked, especially in the presence of neurologic deficits.
  • It further emphasizes the urgent need for additional studies to help better understand, manage, and treat this poorly documented manifestation of ovarian cancer.

Cite This Article

APA
Bernstock JD, Ostby S, Fox B, Sotoudeh H, Janssen A, Kang YJ, Chen J, Prattipati V, Elsayed G, Chagoya G, Yamashita D, Friedman GK, Nabors B, Huh WK, Lobbous M. (2019). Cauda equina syndrome in an ovarian malignant-mixed müllerian tumor with leptomeningeal spread. Clin Case Rep, 7(12), 2341-2345. https://doi.org/10.1002/ccr3.2472

Publication

Clinical case reports
ISSN: 2050-0904
NlmUniqueID: 101620385
Country: England
Language: English
Volume: 7
Issue: 12
Pages: 2341-2345

Researcher Affiliations

Bernstock, Joshua D
  • Department of Neurosurgery Brigham and Women's Hospital Harvard University Boston MA USA.
Ostby, Stuart
  • Division of Gynecologic Oncology University of Alabama at Birmingham Birmingham AL USA.
Fox, Brandon
  • School of Medicine University of Alabama at Birmingham Birmingham AL USA.
Sotoudeh, Houman
  • Department of Radiology, Neuroradiology Section University of Alabama at Birmingham Birmingham AL USA.
Janssen, Andrew
  • School of Medicine University of Alabama at Birmingham Birmingham AL USA.
Kang, Yun Jee
  • Harvard Medical School Boston MA USA.
Chen, Jason
  • Medical Scientist Training Program University of California Los Angeles CA USA.
Prattipati, Veeranjaneyulu
  • Department of Radiology, Neuroradiology Section University of Alabama at Birmingham Birmingham AL USA.
Elsayed, Galal
  • Department of Neurosurgery University of Alabama at Birmingham Birmingham AL USA.
Chagoya, Gustavo
  • Department of Neurosurgery University of Alabama at Birmingham Birmingham AL USA.
Yamashita, Daisuke
  • Department of Neurosurgery Brigham and Women's Hospital Harvard University Boston MA USA.
Friedman, Gregory K
  • Division of Pediatric Hematology and Oncology Department of Pediatrics University of Alabama at Birmingham Birmingham AL USA.
Nabors, Burt
  • Department of Neurology University of Alabama at Birmingham Birmingham AL USA.
Huh, Warner K
  • Division of Gynecologic Oncology University of Alabama at Birmingham Birmingham AL USA.
Lobbous, Mina
  • Department of Neurology University of Alabama at Birmingham Birmingham AL USA.

Conflict of Interest Statement

None declared.

References

This article includes 51 references
  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010.. CA Cancer J Clin 2010 Sep-Oct;60(5):277-300.
    pubmed: 20610543doi: 10.3322/caac.20073google scholar: lookup
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019.. CA Cancer J Clin 2019 Jan;69(1):7-34.
    pubmed: 30620402doi: 10.3322/caac.21551google scholar: lookup
  3. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018.. CA Cancer J Clin 2018 Jul;68(4):284-296.
    pmc: PMC6621554pubmed: 29809280doi: 10.3322/caac.21456google scholar: lookup
  4. Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies.. Nat Rev Cancer 2017 Jan;17(1):65-74.
    pubmed: 27885265doi: 10.1038/nrc.2016.113google scholar: lookup
  5. Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.. Am J Pathol 2016 Apr;186(4):733-47.
    pmc: PMC5808151pubmed: 27012190doi: 10.1016/j.ajpath.2015.11.011google scholar: lookup
  6. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature.. Gynecol Oncol 2012 Apr;125(1):271-7.
    pubmed: 22155675doi: 10.1016/j.ygyno.2011.12.418google scholar: lookup
  7. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature.. Anticancer Res 2005 Sep-Oct;25(5):3553-8.
    pubmed: 16101179
  8. Sanderson A, Bonington SC, Carrington BM, Alison DL, Spencer JA. Cerebral metastasis and other cerebral events in women with ovarian cancer.. Clin Radiol 2002 Sep;57(9):815-9.
    pubmed: 12384107
  9. Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: Review and update on management.. Cancer 2018 Jan 1;124(1):21-35.
    pmc: PMC7418844pubmed: 29165794doi: 10.1002/cncr.30911google scholar: lookup
  10. Liu Y, Wang B, Qian Y, Di D, Wang M, Zhang X. Cauda equine syndrome as the primary symptom of leptomeningeal metastases from lung cancer: a case report and review of literature.. Onco Targets Ther 2018;11:5009-5013.
    pmc: PMC6109657pubmed: 30174438doi: 10.2147/OTT.S165299google scholar: lookup
  11. Alkhotani A, Alrishi N, Alhalabi MS, Hamid T. Cauda Equina Syndrome Secondary to Leptomeningeal Carcinomatosis of Gastroesophageal Junction Cancer.. Case Rep Neurol 2016 Jan-Apr;8(1):87-91.
    pmc: PMC4881252pubmed: 27239185doi: 10.1159/000445869google scholar: lookup
  12. Cantrell LA, Van Le L. Carcinosarcoma of the ovary a review.. Obstet Gynecol Surv 2009 Oct;64(10):673-80; quiz 697.
    pubmed: 19772676doi: 10.1097/OGX.0b013e3181b8aff3google scholar: lookup
  13. Jin Z, Ogata S, Tamura G, Katayama Y, Fukase M, Yajima M, Motoyama T. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.. Int J Gynecol Pathol 2003 Oct;22(4):368-73.
    pubmed: 14501818doi: 10.1097/01.pgp.0000092134.88121.56google scholar: lookup
  14. Shepherd JH. Revised FIGO staging for gynaecological cancer.. Br J Obstet Gynaecol 1989 Aug;96(8):889-92.
    pubmed: 2775686doi: 10.1111/j.1471-0528.1989.tb03341.xgoogle scholar: lookup
  15. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed müllerian tumors treated with platinum-based chemotherapy.. Obstet Gynecol 1995 May;85(5 Pt 1):735-9.
    pubmed: 7724104doi: 10.1016/0029-7844(95)00038-sgoogle scholar: lookup
  16. Inthasorn P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy.. Aust N Z J Obstet Gynaecol 2003 Feb;43(1):61-4.
    pubmed: 12755351doi: 10.1046/j.0004-8666.2003.00003.xgoogle scholar: lookup
  17. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, Edwards RP. Chemotherapy for malignant mixed Müllerian tumors of the ovary.. Gynecol Oncol 2000 Nov;79(2):196-200.
    pubmed: 11063643doi: 10.1006/gyno.2000.5956google scholar: lookup
  18. Harris MA, Delap LM, Sengupta PS, Wilkinson PM, Welch RS, Swindell R, Shanks JH, Wilson G, Slade RJ, Reynolds K, Jayson GC. Carcinosarcoma of the ovary.. Br J Cancer 2003 Mar 10;88(5):654-7.
    pmc: PMC2376340pubmed: 12618869doi: 10.1038/sj.bjc.6600770google scholar: lookup
  19. Chang J, Sharpe JC, A'Hern RP, Fisher C, Blake P, Shepherd J, Gore ME. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients.. Ann Oncol 1995 Oct;6(8):755-8.
    pubmed: 8589011doi: 10.1093/oxfordjournals.annonc.a059312google scholar: lookup
  20. Barnholtz-Sloan JS, Morris R, Malone JM Jr, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).. Gynecol Oncol 2004 May;93(2):506-12.
    pubmed: 15099970doi: 10.1016/j.ygyno.2004.02.016google scholar: lookup
  21. Miller E, Dy I, Herzog T. Leptomeningeal carcinomatosis from ovarian cancer.. Med Oncol 2012 Sep;29(3):2010-5.
    pubmed: 21983859doi: 10.1007/s12032-011-0076-9google scholar: lookup
  22. Krupa M, Byun K. Leptomeningeal carcinomatosis and bilateral internal auditory canal metastases from ovarian carcinoma.. Radiol Case Rep 2017 Jun;12(2):386-390.
    pmc: PMC5417755pubmed: 28491194doi: 10.1016/j.radcr.2017.03.013google scholar: lookup
  23. Cormio G, Maneo A, Parma G, Pittelli MR, Miceli MD, Bonazzi C. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review.. Ann Oncol 1995 Jul;6(6):571-4.
    pubmed: 8573536doi: 10.1093/oxfordjournals.annonc.a059246google scholar: lookup
  24. Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.. Proc Natl Acad Sci U S A 2016 Oct 25;113(43):12238-12243.
    pmc: PMC5087050pubmed: 27791010doi: 10.1073/pnas.1614120113google scholar: lookup
  25. Ardighieri L, Mori L, Conzadori S, Bugatti M, Falchetti M, Donzelli CM, Ravaggi A, Odicino FE, Facchetti F. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.. Virchows Arch 2016 Jul;469(1):61-9.
    pubmed: 27059324doi: 10.1007/s00428-016-1933-xgoogle scholar: lookup
  26. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.. J Clin Oncol 2015 Dec 1;33(34):4015-22.
    pubmed: 26351349doi: 10.1200/JCO.2015.62.3397google scholar: lookup
  27. Le Roux PD, Jardine DS, Kanev PM, Loeser JD. Pediatric intracranial pressure monitoring in hypoxic and nonhypoxic brain injury.. Childs Nerv Syst 1991 Feb;7(1):34-9.
    pubmed: 2054806doi: 10.1007/BF00263831google scholar: lookup
  28. Toft E, Sinkjaer T, Rasmussen A. Stretch reflex variation in the relaxed and the pre-activated quadriceps muscle of normal humans.. Acta Neurol Scand 1991 Oct;84(4):311-5.
    pubmed: 1772004doi: 10.1111/j.1600-0404.1991.tb04960.xgoogle scholar: lookup
  29. Mittica G, Genta S, Aglietta M, Valabrega G. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. Int J Mol Sci 2016 Jul 20;17(7).
    pmc: PMC4964540pubmed: 27447625doi: 10.3390/ijms17071169google scholar: lookup
  30. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis.. J Neurooncol 1998 Jun-Jul;38(2-3):245-52.
    pubmed: 9696379doi: 10.1023/a:1005956925637google scholar: lookup
  31. Chamberlain MC. Neoplastic meningitis.. Oncologist 2008 Sep;13(9):967-77.
    pubmed: 18776058doi: 10.1634/theoncologist.2008-0138google scholar: lookup
  32. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology.. Neurology 1979 Oct;29(10):1369-75.
    pubmed: 573381doi: 10.1212/wnl.29.10.1369google scholar: lookup
  33. Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment.. Semin Oncol 2006 Jun;33(3):312-23.
    pubmed: 16769420doi: 10.1053/j.seminoncol.2006.04.016google scholar: lookup
  34. Gleissner B, Chamberlain MC. Neoplastic meningitis.. Lancet Neurol 2006 May;5(5):443-52.
    pubmed: 16632315doi: 10.1016/S1474-4422(06)70443-4google scholar: lookup
  35. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine.. Br J Cancer 2001 Jan;84(2):157-63.
    pmc: PMC2363714pubmed: 11161370doi: 10.1054/bjoc.2000.1574google scholar: lookup
  36. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy.. Arch Neurol 1998 Apr;55(4):506-12.
    pubmed: 9561978doi: 10.1001/archneur.55.4.506google scholar: lookup
  37. Chamberlain MC, Kormanik PR. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy.. J Neurooncol 1997 Oct;35(1):55-64.
    pubmed: 9266441doi: 10.1023/a:1005803918194google scholar: lookup
  38. Stein M, Steiner M, Ben-Schachar M, Kuten A, Malberger E, Goldsher D, Robinson E. Leptomeningeal involvement by epithelial ovarian carcinoma: a case report.. Gynecol Oncol 1987 Jun;27(2):241-5.
    pubmed: 3570063doi: 10.1016/0090-8258(87)90299-xgoogle scholar: lookup
  39. Murthy LK, Chandrashekar HR, Hiremath SS, Shashikala P, Arun KN. Meningeal carcinomatosis complicating ovarian malignancy.. J Assoc Physicians India 1991 Oct;39(10):773-4.
    pubmed: 1816207
  40. Delord JP, Fizazi K, el Hajj M, Pautier P, Lhommé C. Isolated leptomeningeal metastasis from ovarian carcinoma: an unusual event.. Eur J Cancer 1998 Apr;34(5):758-9.
    pubmed: 9713288doi: 10.1016/s0959-8049(97)10051-xgoogle scholar: lookup
  41. Ohta H, Koyama R, Nagai T, Hirayama Y, Saito S, Yonesaka A. Meningeal carcinomatosis from an ovarian primary with complete response to adjuvant chemotherapy after cranial irradiation.. Int J Clin Oncol 2001 Jun;6(3):157-62.
    pubmed: 11706787doi: 10.1007/pl00012100google scholar: lookup
  42. Melichar B, Tomsová M, Rehák S, Malírová E, Simonová G. Meningeal carcinomatosis as a late complication of brain metastases of epithelial ovarian carcinoma.. Eur J Gynaecol Oncol 2008;29(4):402-4.
    pubmed: 18714581
  43. Jackson P. Carcinomatous meningitis associated with carcinoma of the ovary. Case report.. Br J Obstet Gynaecol 1984 Aug;91(8):824-5.
    pubmed: 6466587doi: 10.1111/j.1471-0528.1984.tb04860.xgoogle scholar: lookup
  44. Gordon AN, Kavanagh JJ Jr, Wharton JT, Rutledge FN, Obbens EA, Bodey GP Sr. Successful treatment of leptomeningeal relapse of epithelial ovarian cancer.. Gynecol Oncol 1984 May;18(1):119-24.
    pubmed: 6714801doi: 10.1016/0090-8258(84)90015-5google scholar: lookup
  45. Behnam K, Aguilera AJ, Kornfeld M, Jordan SW, Hilgers RD. Meningeal carcinomatosis from an ovarian primary: a clinicopathologic study.. Gynecol Oncol 1984 Sep;19(1):104-9.
    pubmed: 6469084doi: 10.1016/0090-8258(84)90165-3google scholar: lookup
  46. Bakri YN, Lee JH Jr, Lewis GC Jr, Lublin FD, Danoff B. Meningeal carcinomatosis complicating gynecologic malignancies: a literature review and report of a case.. Obstet Gynecol Surv 1983 Jan;38(1):1-5.
    pubmed: 6338426doi: 10.1097/00006254-198301000-00001google scholar: lookup
  47. Mayer RJ, Berkowitz RS, Griffiths CT. Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease.. Cancer 1978 Feb;41(2):776-83.
    pubmed: 630551doi: 10.1002/1097-0142(197802)41:2<776::aid-cncr2820410253>3.0.co;2-egoogle scholar: lookup
  48. Zibetti Dal Molin G, Abrahão CM, Coleman RL, Maluf FC. Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma.. Gynecol Oncol Res Pract 2018;5:6.
    pmc: PMC6098839pubmed: 30147940doi: 10.1186/s40661-018-0063-3google scholar: lookup
  49. Grant R, Naylor B, Greenberg HS, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis.. Arch Neurol 1994 May;51(5):457-61.
    pubmed: 8179494doi: 10.1001/archneur.1994.00540170033013google scholar: lookup
  50. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J, Vecht ChJ. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study.. Eur J Cancer 2004 Dec;40(18):2726-33.
    pubmed: 15571954doi: 10.1016/j.ejca.2004.08.012google scholar: lookup
  51. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?. J Neurooncol 1998 Jun-Jul;38(2-3):151-7.
    pubmed: 9696366doi: 10.1023/a:1005999228846google scholar: lookup

Citations

This article has been cited 1 times.
  1. Stopa BM, Cuoco JA, Adhikari S, Grider DJ, Rogers CM, Marvin EA. Iatrogenic Leptomeningeal Carcinomatosis Following Craniotomy for Resection of Metastatic Serous Ovarian Carcinoma: A Systematic Literature Review and Case Report.. Front Surg 2022;9:850050.
    doi: 10.3389/fsurg.2022.850050pubmed: 35548192google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.